The emergence of drugs inhibiting the JAK-STAT pathway has culminated in tyrosine kinase 2 inhibitors targeting PsA, lupus and other indications, according to Grace C. Wright, MD, PhD, FACR.

The JAK/STAT (Janus Kinase-Signal Transducer and Activator of Transcription) signalling pathway controls the activity of various cytokines and growth factors. The Atomic Structure of Janus Kinase 1.

Gadina noted that, despite the regimented categorizations applied to JAK inhibitors — JAK1, JAK2, JAK3 and TYK2 — such labels, and the drugs they describe, are far from straightforward.

Min X, Ungureanu D, Maxwell S, et al. Structural and functional characterization of the JH2 pseudokinase domain of JAK family tyrosine kinase 2 (TYK2). The Journal of Biological Chemistry. 2015 ...

JAK/TYK2 inhibitors are associated with on-target safety signals, including opportunistic infections and dysregulated hematologic homeostasis (anemia, thrombocytopenia). Poster Presentation Details: ...

It signals through the JAK-STAT pathway, in particular, TYK2, one of the Janus kinases. If you have a small molecule inhibitor of TYK2, at least theoretically, there's opportunity for an oral ...

The agency approved delgocitinib cream 2% (Anzupgo) for adults with moderate-to-severe CHE, according to a statement from LEO Pharma. Approval of the multitargeted JAK-STAT pathway inhibitor ...

As a non-receptor tyrosine kinase, TYK2 is a member of the JAK kinase family, which is an important kinase on the JAK-STAT signaling pathway, playing an important role in the pathogenesis of ...

Meeting Coverage > EADV JAK Agents Impress in Alopecia Areata — Significant hair growth with two different drugs by Charles Bankhead, Senior Editor, MedPage Today September 17, 2018 ...

News provided by Recludix Pharma, Inc. Oct 31, 2023, 4:00 PM ET - REX-7117 found to have superior efficacy to a clinically-relevant dose of deucravacitinib in a preclinical model of psoriasis ...

News provided by Recludix Pharma, Inc. Oct 31, 2023, 4:00 PM ET - REX-7117 found to have superior efficacy to a clinically-relevant dose of deucravacitinib in a preclinical model of psoriasis ...